<DOC>
	<DOCNO>NCT00168714</DOCNO>
	<brief_summary>The primary objective study prospectively record analyze birth defect spontaneous fetal loss woman multiple sclerosis ( MS ) expose Avonex within approximately 1 week conception first trim pregnancy , outcome pregnancy unknown prospectively prospectively record analyze pregnancy outcomes exploratory fashion woman MS stop therapy , may expose Avonex approximately 1 week conception first trim pregnancy .</brief_summary>
	<brief_title>Pregnancy Exposure Registry Avonex ( Interferon Beta-1a )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Prenatal Exposure Delayed Effects</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Have expose AVONEX within approximately 1 week conception first trim pregnancy . Provide sufficient information determine pregnancy prospectively register ( i.e. , outcome pregnancy must unknown prospectively ) . Provide verbal consent participate Registry . Verbally provide contact information , HCP , infant 's HCP ( applicable ) . NOTE : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>AVONEX</keyword>
	<keyword>Pregnancy</keyword>
</DOC>